Nonalcoholic fatty liver disease – a serious comorbidity of diabesis
Authors:
Mária Belovičová 1,2,3; Valéria Mašterová 4,5
Authors‘ workplace:
Bardejovské Kúpele a. s.
1; Interná ambulancia so zameraním na diagnostiku a liečbu chorôb pečene, Remedium s. r. o.
2; VŠ zdravotníctva a sociálnej práce sv. Alžbety Bratislava, pracovisko Bardejov a Michalovce
3; VŠ zdravotníctva a sociálnej práce sv. Alžbety Bratislava
4; Fakulta zdravotníckych odborov, Prešovská univerzita
5
Published in:
Forum Diab 2016; 5(1): 45-48
Category:
Topic
Overview
NAFLD – non-alcoholic fatty liver disease – represent a wide spectrum of clinical and pathological conditions (simple steatosis – steatohepatitis – hepatic cirrhosis and its complications). Risk factors for the development of NAFLD include: obesity, diabetes mellitus (DM) type 2, hypertriglyceridemia. NAFLD mainly associated with type 2 diabetes and the metabolic syndrome is the most common chronic diseases worldwide which affects 15–40 % of the world population. Transient elastography (TE) is a painless non –invasive methodology, which measures the stiffness of the liver tissue. It can be used in monitoring of the patient and also such a screening of chronic liver diseases. Given the high prevalence of NAFLD in patients with type 2 diabetes, these patients may benefit from screening of liver disease through TE. Interdisciplinary cooperation is needed for early diagnosis and prevention of NAFLD and its late complications. The authors briefly review the clinical picture, diagnosis and treatment of NAFLD .
Key words:
NAFLD – Nonalcoholic fatty liver disease – transient elastography – diabetes mellitus – obesity
Sources
1. Ginter E, Šimko V, Kajaba I. 21. storočie. Pandémia abdominálnej obezity. MM 2011; 1–2: 15–18.
2. Avdičová M et al. Monitorovanie rizikových faktorov chronických chorôb v SR. Slovenská spoločnosť praktickej obezitológie: Svidník 2013. ISBN 978–80–971460–0-9.
3. Krahulec B, Fábryová Ľ, Holéczy P et al. Klinická obezitológia. Facta Medica: Brno 2013. ISBN 978–80–904731–7-1.
4. Krahulec B. Obezita a diabetes mellitus. Dni praktickej obezitológie 2014. Zborník abstraktov konferencie. Slovenská spoločnosť praktickej obezitológie: Bardejov 2014: 49–50. ISBN 978–80–971460–1-6.
5. James WP. The epidemiology of obesity: the size of the problem. J Intern Med 2008; 263(4): 336–352.
6. Dvořák K. Nealkoholická steatohepatitida (NASH) – týká se nás všech. Gastroent Hepatol 2012; 66(5): 377–383.
7. Dvořák K. Nealkoholové postižení jater při steatóze. Medicína po promoci 2013; 14(Suppl 2): 23–27.
8. Belovičová M, Gracová A, Švirková H. Poškodenie pečene u obéznych detí. Vědecká konference Metabolický syndrom – mezioborový problém. Med Sport Boh Slov 2014; 23(3): 112–114.
9. Dvořák K. Možnosti neinvazivní diagnostiky u NAFLD. Gastroent Hepatol 2015; 69(2): 110–115.
10. Brúha R. Screening jaterního poškození u pacientů s diabetes mellitus 2. typu. Gastroent Hepatol 2015; 69(4): 365–367.
11. Brůha R, Dvořák K, Petrtýl J. Onemocnění jater u diabetiků. Vnitř Lék 2013; 59(7): 546–550
12. Brůha R. Přístup k pacientům s jaterními chorobami. Vnitř Lék 2015; 61(Suppl 4): 4S6–4S12.
13. Tolman KG, Fonseca V, Dalpiaz A et al. Spectrum of liver disease in type 2 diabetes and management of patient with diabetes and liver disease. Diabetes Care 2007; 30(3): 734–743.
14. Delorme S, Debus J. Sonographie. 2nd ed. Thieme: Stuttgart 2004. ISBN 3–13–136952–3.
15. Belovičová M, Belovičová L, Švirková H. Transient elastography in diagnostic of NAFLD in obese patients – our experience. Clin Exp Hepatology 2015; 1(2): 75.
16. Belovičová M, Belovičová L. Nefarmakologická liečba obezity. Interná Med 2015; 15(9): 405–408.
17. Angulo P, Hui JM, Marchesini G et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45(4): 846–854.
18. Hainer V et al. Základy klinické obezitologie. 2. ed. Grada: Praha 2011. ISBN 978–80–247–3252–7.
19. Blachier M, Leleu H, Peck-Radosavljevic M et al. The Burden of liver disease in Europe 2013. A review of available epidemiological data. J Hepatol 2013; 58(3): 593–608.
20. Belovičová M. Nealkoholová tuková choroba pečene ako závažná komorbidita pri obezite a diabete mellite 2.typu. XIII. Slovenské obezitologické dni s medzinárodnou účasťou. Trnava 13.-14. 11. 2015. Zborník abstraktov: 16.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Forum Diabetologicum
![Issue 1](https://www.forumdiabetologicum.sk/media/cache/resolve/journal_issue/media/image_pdf/abcc521b121f74722af2a2d608f92040.jpeg)
2016 Issue 1
Most read in this issue
- New drugs in the treatment of obesity: their availability for clinical practice
- GLP1-analogs – suitable choice in obese patients with type 2 diabetes mellitus
- Nonalcoholic fatty liver disease – a serious comorbidity of diabesis
- Metabolic changes after bariatric/metabolic operations